Get started
Author

Ahmadul Kadir

Observed name: A. Kadir
OpenAlex ID: A5021401570
The use of PET in Alzheimer disease
2010 · Agneta Nordberg, Juha O. Rinne, et al. · Nature Reviews Neurology · 449
Age, Frailty, and Comorbidity as Prognostic Factors for Short-Term Outcomes in Patients With Coronavirus Disease 2019 in Geriatric Care
2020 · Sara Hägg, Juulia Jylhävä, et al. · Journal of the American Medical Directors Association · 190
PDF
Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimer’s Disease
2012 · Maria Eriksdotter-Jönhagen, Bengt Linderoth, et al. · Dementia and Geriatric Cognitive Disorders · 158
Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease
2010 · Ahmadul Kadir, Ove Almkvist, et al. · Neurobiology of Aging · 154
PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease
2006 · Ahmadul Kadir, Ove Almkvist, et al. · Psychopharmacology · 146
Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease
2010 · Ahmadul Kadir, Amelia Marutle, et al. · Brain · 140
PDF
Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device
2016 · Helga Eyjolfsdottir, Maria Eriksdotter, et al. · Alzheimer s Research & Therapy · 137
PDF
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease
2008 · Ahmadul Kadir, Niels Andreasen, et al. · Annals of Neurology · 133
PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD
2007 · A. Kadir, T. Darreh-Shori, et al. · Neurobiology of Aging · 103
Target-Specific PET Probes for Neurodegenerative Disorders Related to Dementia
2010 · Ahmadul Kadir, Agneta Nordberg · Journal of Nuclear Medicine · 64
PDF
Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease
2015 · Azadeh Karami, Helga Eyjolfsdottir, et al. · Alzheimer s & Dementia · 63
Changes in brain 11C–nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET
2007 · Ahmadul Kadir, Taher Darreh-Shori, et al. · Psychopharmacology · 63
Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine
2006 · T. Darreh-Shori, A. Kadir, et al. · Neurobiology of Aging · 63
Long-term Effects of Galantamine Treatment on Brain Functional Activities as Measured by PET in Alzheimer's Disease Patients
2011 · Connor Keller, Ahmadul Kadir, et al. · Journal of Alzheimer s Disease · 59
Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE ε4 allele, in relation to cognitive function and cerebral glucose metabolism
2006 · T. Darreh-Shori, S. Brimijoin, et al. · Neurobiology of Disease · 52
Clinical impact of 18F-FDG-PET among memory clinic patients with uncertain diagnosis
2020 · Giulia Perini, Elena Rodriguez-Vieitez, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 30
PDF
CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease
2019 · Azadeh Karami, Maria Eriksdotter, et al. · Frontiers in Molecular Neuroscience · 27
PDF
Correlations between Alzheimer’s Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment
2015 · Agneta Nordberg, Ahmadul Kadir, et al. · Journal of Alzheimer s Disease · 9
PET imaging of cortical 11C-nicotine binding correlates with cognitive function of attention in Alzheimer's disease
2006 · Ahmadul Kadir, O. Almkvist, et al. · NeuroImage · 8
P2‐109: Csf Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer's Disease
2019 · Azadeh Karami, Maria Eriksdotter, et al. · Alzheimer s & Dementia
Degree of abnormality is associated with rate of change in measures of beta-amyloid, glucose metabolism and cognition in an autopsy-verified Alzheimer’s disease case
2014 · Ove Almkvist, Ahmadul Kadir, et al. · Neurocase
P2‐387: Ngf Cell Therapy in Ad Patients: Effects on Csf Cholinergic Biomarkers
2014 · Azadeh Karami, Helga Eyjolfsdottir, et al. · Alzheimer s & Dementia
Front & Back Matter
2012 · B. Guarnieri, F. Adorni, et al. · Dementia and Geriatric Cognitive Disorders
P4‐358: Different hierarchical cytoarchitectonic sub‐type vulnerability to Aβ‐deposits and gray matter loss in AD and MCI patients: A comparison between a young and old cohort
2011 · Yen‐Bee Ng, Agneta Nordberg, et al. · Alzheimer s & Dementia
PDF
P3‐427: Nerve growth factor treatment in Alzheimer's disease: Effects on EEG
2011 · Helga Eyjolfsdottir, Maria Eriksdotter Jonhagen, et al. · Alzheimer s & Dementia
PDF
Works count: 38
Citation count: 2,048
H-index: 17
I10-index: 17
Year
Topic
Type